This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real‐world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Issue 10 (17th September 2020)
Record Type:
Journal Article
Title:
Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real‐world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Issue 10 (17th September 2020)
Main Title:
Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real‐world cohort of hepatitis B virus associated hepatocellular carcinoma patients
Abstract : The above article from British Journal of Clinical Pharmacology, published online on July 5, 2020 in Wiley Online Library (http://wileyonlinelibrary.com ) has been withdrawn by agreement among the authors and John Wiley & Sons Ltd on behalf of the British Pharmacology Society. The withdrawal has been agreed in accordance with the authors' decision to revise their study providing the latest data.